help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saceda, M.
Right arrow Articles by Martin, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saceda, M.
Right arrow Articles by Martin, M. B.

Endocrinology, Vol 137, 4322-4330, Copyright © 1996 by Endocrine Society


ARTICLES

Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines

M Saceda, TW Grunt, R Colomer, ME Lippman, R Lupu and MB Martin
Vincent T. Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA.

Expression of the erbB-2 oncogene in breast cancer patients correlates with poor prognosis and failure of hormonal therapy. In this study, the effects of a putative erbB/HER ligand, gp30, on estrogen receptor (ER) concentration and activity was investigated in the estrogen receptor positive human breast cancer cells, BT474 and MCF-7, which express either high or low levels of erbB-2 and erbB-4, respectively. Treatment of cells with gp30 resulted in a decrease in the steady-state level of estrogen receptor protein by approximately 70-80%. The effect of gp30 on the concentration of ER was independent of serum in the media and was not inhibited by an epidermal growth factor receptor blocking antibody. In addition to the effect on ER protein, gp30 decreased the steady-state level of ER messenger RNA. Transcription run on experiments demonstrated that the decrease in ER expression was mediated by a decrease in ER gene transcription. The effect of gp30 on estrogen receptor activity was also investigated in this study. Treatment of cells with gp30 blocked estradiol induction of progesterone receptor. Inhibition was observed at the level of progesterone receptor protein, messenger RNA, and gene transcription. gp30 also blocked estradiol induction of pS2 gene transcription. In addition to its effects on progesterone receptor and pS2, gp30 blocked activation of an estrogen response element in a transient transfection assay and inhibited ER binding to its response element in a DNA mobility shift assay, suggesting a direct effect on the estrogen receptor. The effects of gp30 on estrogen receptor concentration and activity were independent of the level of erbB-2 and erbB-4 in the cell. These data show that gp30 regulates the concentration of ER and modulates ER activity.


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
S. Guo and G. E. Sonenshein
Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway
Mol. Cell. Biol., October 1, 2004; 24(19): 8681 - 8690.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Argiris, C.-X. Wang, S. G. Whalen, and M. P. DiGiovanna
Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)
Clin. Cancer Res., February 15, 2004; 10(4): 1409 - 1420.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Labriola, M. Salatino, C. J. Proietti, A. Pecci, O. A. Coso, A. R. Kornblihtt, E. H. Charreau, and P. V. Elizalde
Heregulin Induces Transcriptional Activation of the Progesterone Receptor by a Mechanism That Requires Functional ErbB-2 and Mitogen-Activated Protein Kinase Activation in Breast Cancer Cells
Mol. Cell. Biol., February 1, 2003; 23(3): 1095 - 1111.
[Abstract] [Full Text]


Home page
Mol Cancer ResHome page
E. Atlas, M. Cardillo, I. Mehmi, H. Zahedkargaran, C. Tang, and R. Lupu
Heregulin Is Sufficient for the Promotion of Tumorigenicity and Metastasis of Breast Cancer Cells in Vivo
Mol. Cancer Res., January 1, 2003; 1(3): 165 - 175.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
M. D. Schroeder, J. Symowicz, and L. A. Schuler
PRL Modulates Cell Cycle Regulators in Mammary Tumor Epithelial Cells
Mol. Endocrinol., January 1, 2002; 16(1): 45 - 57.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. S. Oh, L. A. Lorant, J. N. Holloway, D. L. Miller, F. G. Kern, and D. El-Ashry
Hyperactivation of MAPK Induces Loss of ER{alpha} Expression in Breast Cancer Cells
Mol. Endocrinol., August 1, 2001; 15(8): 1344 - 1359.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M.A. Habiba, S.C. Bell, and F. Al-Azzawi
The effect of hormone replacement therapy on the immunoreactive concentrations in the endometrium of oestrogen and progesterone receptor, heat shock protein 27, and human {beta}-lactoglobulin
Hum. Reprod., January 1, 2000; 15(1): 36 - 42.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Scholz, M. Truss, and M. Beato
Hormone-induced Recruitment of Sp1 Mediates Estrogen Activation of the Rabbit Uteroglobin Gene in Endometrial Epithelium
J. Biol. Chem., February 20, 1998; 273(8): 4360 - 4366.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Stoica, M. Saceda, A. Fakhro, H. B. Solomon, B. D. Fenster, and M. B. Martin
The Role of Transforming Growth Factor-{beta} in the Regulation of Estrogen Receptor Expression in the MCF-7 Breast Cancer Cell Line
Endocrinology, April 1, 1997; 138(4): 1498 - 1505.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society